Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Gross Margin (2020 - 2025)

Gyre Therapeutics (GYRE) has disclosed Gross Margin for 6 consecutive years, with 35.97% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 5981.0% to 35.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 76.42% through Dec 2025, down 1991.0% year-over-year, with the annual reading at 44.09% for FY2025, 5223.0% down from the prior year.
  • Gross Margin for Q4 2025 was 35.97% at Gyre Therapeutics, down from 94.67% in the prior quarter.
  • The five-year high for Gross Margin was 150.1% in Q4 2021, with the low at 0.89% in Q1 2021.
  • Average Gross Margin over 5 years is 71.46%, with a median of 95.59% recorded in 2025.
  • The sharpest move saw Gross Margin tumbled -10275bps in 2022, then surged 9599bps in 2023.
  • Over 5 years, Gross Margin stood at 150.1% in 2021, then tumbled by -68bps to 47.35% in 2022, then soared by 101bps to 95.4% in 2023, then rose by 0bps to 95.78% in 2024, then crashed by -62bps to 35.97% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 35.97%, 94.67%, and 95.7% for Q4 2025, Q3 2025, and Q2 2025 respectively.